<DOC>
	<DOCNO>NCT02171546</DOCNO>
	<brief_summary>Part 1 : To investigate effect quinidine , P-glycoprotein ( P-gp ) probe inhibitor bioavailability dabigatran etexilate , Part 2 : To determine effect quinidine bioavailability fexofenadine , probe substrate P-gp</brief_summary>
	<brief_title>Relative Bioavailability Dabigatran Etexilate Capsules With Without Quinidine Sulfate Tablets Measure Effect Quinidine Absorption Fexofenadine Healthy Male Female Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Quinidine</mesh_term>
	<mesh_term>Fexofenadine</mesh_term>
	<mesh_term>Terfenadine</mesh_term>
	<mesh_term>Quinidine gluconate</mesh_term>
	<criteria>1 . Healthy male female accord follow criterion : Based upon complete medical history , include physical examination , vital sign ( BP , PR ) , 12lead ECG , clinical laboratory test ; 2 . Age ≥18 Age ≤55 year ; 3 . Body Mass Index ( BMI ) ≥18.5 BMI &lt; 30 kg/m2 ; 4 . Signed date write informed consent prior admission study accordance GCP local legislation ; 5 . If female childbearing potential , pregnant breast feeding , plan become pregnant duration study 2 month receive last dose study drug , negative serum pregnancy test within 14 day treatment , prior dosing ; 6 . Females childbearing potential willing use adequate contraception , define use hormonal ( oral , injectable implantable ) barrier method contraceptive , intrauterine device agree use method contraception least 2 month drug administration . Women undergone total hysterectomy , history bilateral tubal ligation least 2 year postmenopausal consider childbearing potential . 1 . Any finding medical examination ( include BP , PR ECG ) deviate normal clinical relevance ; 2 . Any evidence clinically relevant concomitant disease ; 3 . Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder ; 4 . Surgery gastrointestinal tract ( except appendectomy ) ; 5 . Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder ; 6 . History relevant orthostatic hypotension , faint spell blackout ; 7 . Chronic relevant acute infection ; 8 . History relevant allergy/hypersensitivity ( include allergy drug excipients ) ; 9 . Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior administration trial ; 10 . Use drug might reasonably influence result trial prolong QT/QTc interval base knowledge time protocol preparation within 10 day prior administration trial ; 11 . Participation another trial investigational drug within two month prior administration trial ; 12 . Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) ; 13 . Inability refrain smoke trial day ; 14 . Alcohol abuse ( 60 g/day ) ; 15 . Drug abuse ; 16 . Blood donation ( 100 mL within four week prior administration trial ) ; 17 . Excessive physical activity ( within one week prior administration trial ) ; 18 . Any laboratory value outside reference range clinical relevance ; 19 . Inability comply dietary regimen trial site ; 20 . A marked baseline prolongation QT/QTc interval ( e.g. , repeated demonstration QTc interval &gt; 450 m ) ; 21 . A history additional risk factor Torsades de Pointes ( e.g. , heart failure , hypokalemia , family history Long QT Syndrome ) ; 22 . Taking drug know Pgp inhibitor inducer ( verapamil , phenothiazine antipsychotic , erythromycin , antifungal drug St. John´s Wort ) within last 4 week screen ; 23 . Chronic use oral contraception contain ethinyl estradiol method contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>